Literature DB >> 9241388

Factors associated with client-reported HIV infection among clients entering methadone treatment.

R J MacGowan1, R R Fichtner, N Swanson, C Collier, A Kroliczak, G Cole.   

Abstract

To determine demographic and behavioral factors associated with client-reported HIV infection among new enrollees in methadone maintenance treatment programs (MMTPs) in Massachusetts and Connecticut, we examined ethnographic data and interview data from MMTP clients (N = 674). Clients responded to questions about behaviors in the 30 days before drug treatment. ETHNOGRAPH was used to analyze qualitative data, and logistic regression analysis was used to identify variables associated with client-reported HIV infection. Statistical significance was set at p < .05. The client-reported HIV infection rate was 20% (132/674). Odds ratios for factors associated with client-reported HIV infection were being white (0.53), increase in age (1.07), use of non-injected heroin (0.12), use of injected heroin (6.24), cocaine injection (1.78), sharing of "works" with strangers (2.15), and "safer sex" behavior (4.04). Additionally, 35% of those who did not use illicit drugs reported being seropositive. The qualitative data suggested HIV positive clients were concerned about protecting sex partners, and learning of HIV infection motivated some to stop using drugs. Although some clients engaged in low-risk behaviors, others did not, therefore the potential for HIV transmission among injection drug users (IDUs) in Connecticut and Massachusetts exists. HIV prevention and drug treatment program personnel should reinforce and build on the low-risk behaviors that are acceptable and adopted by some in this population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241388

Source DB:  PubMed          Journal:  AIDS Educ Prev        ISSN: 0899-9546


  6 in total

Review 1.  Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system.

Authors:  Michelle A Patriquin; Isabelle E Bauer; Jair C Soares; David P Graham; David A Nielsen
Journal:  Psychiatr Genet       Date:  2015-10       Impact factor: 2.458

2.  Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; Zachary Feldman; Joseph F Cubells; Rhonda Pruzinsky; Kishorchandra Gonsai; Christopher Cargile; Mehmet Sofuoglu; Mohit P Chopra; Gerardo Gonzalez-Haddad; Kathleen M Carroll; Thomas R Kosten
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

3.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

4.  Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

Authors:  Thomas R Kosten; Guiying Wu; Wen Huang; Mark J Harding; Sara C Hamon; Jaakko Lappalainen; David A Nielsen
Journal:  Biol Psychiatry       Date:  2012-08-18       Impact factor: 13.382

5.  ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.

Authors:  Catherine J Spellicy; Thomas R Kosten; Sara C Hamon; Mark J Harding; David A Nielsen
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

6.  Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients.

Authors:  Thomas S Atkinson; Nichole Sanders; Michael Mancino; Alison Oliveto
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.